Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5848MR)

This product GTTS-WQ5848MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5848MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4889MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ9523MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ5349MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8065MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3590MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ6577MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ10905MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ3094MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW